Jumpcan subsidiaries reinvest 20m yuan from idle funds into new products

Hubei Jumpcan Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiaries, Jichuan (Shanghai) Medical Technology Co., Ltd. and Jichuan Pharmaceutical Group Co., Ltd., have redeemed earlier cash management products. The redemptions totalled 112m yuan, yielding profits of 129,100 yuan, 292,600 yuan, and 616,400 yuan, with annualized yields ranging from 1.20% to 2.50%. These redemptions align with the company's strategy to maximize the efficiency of its idle raised funds.

Following the redemptions, Jichuan Pharmaceutical Group Co., Ltd. and Jichuan (Shanghai) Medical Technology Co., Ltd. each invested 10m yuan (a total of 20m yuan) into two new 181-day structured deposit products with Bohai Bank Taizhou Branch. These products are principal-protected with floating returns, offering an expected annualized yield of 1.00% to 2.00%. The investment period for both products is from September 2, 2025, to March 2, 2026.

This cash management initiative, which uses a portion of the 1,383,772,031.38 yuan net proceeds from a 2020 non-public issuance, was approved by the company's board, supervisory board, and shareholders. It adheres to internal policies for managing idle raised funds, focusing on low-risk, liquid investments without affecting ongoing project implementation. As of June 30, 2025, the company's asset-liability ratio stood at 18.85%.